Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Blocking Constant Interferon Signaling Allows the Immune System to Clear Chronic Viral Infections

By BiotechDaily International staff writers
Posted on 23 Apr 2013
Blocking constant Type I interferon (IFN-I) signaling in mice diminished chronic immune activation and immune suppression and enabled the animals' immune system to rejuvenate and ultimately clear persistent viral infections.

Interferons (IFNs) are glycoprotein cytokines made and released by host cells in response to the presence of pathogens such as viruses, bacteria, parasites, or tumor cells. They allow for communication between cells to trigger the protective defenses of the immune system that eradicate pathogens or tumors. Interferons were named after their ability to "interfere" with viral replication within host cells. IFNs have other functions: they activate immune cells, such as natural killer cells and macrophages; they increase recognition of infection or tumor cells by up-regulating antigen presentation to T-lymphocytes; and they increase the ability of uninfected host cells to resist new viral infection. Certain symptoms, such as aching muscles and fever, are related to the production of IFNs during infection. While Type I interferons (IFN-I) are critical for antiviral immunity, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections.

Investigators at the University of California, Los Angeles (USA) injected mice suffering from chronic viral infections with an antibody that temporarily blocked IFN-I activity.

They reported in the April 12, 2013, issue of the journal Science that the blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T-cells and was associated with enhanced IFN-gamma production.

“When cells confront viruses, they produce Type I interferons, which trigger the immune system’s protective defenses and sets off an alarm to notify surrounding cells,” said senior author Dr. David Brooks, assistant professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles. “Type-I interferon is like the guy in the watch tower yelling, "Red alert,” when the marauders try to raid the castle.”

“What we saw was entirely illogical,” said Dr. Brooks. “We had blocked something critical for infection control and expected the immune system to lose the fight against infection. Instead, the temporary break in IFN-I signaling improved the immune system’s ability to control infection. Our next task will be to figure out why and how to harness it for therapies to treat humans.”

Related Links:
University of California, Los Angeles



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.